Approximately one in 30 NIH-funded clinical trials—and more than 74,000 trial participants—were affected by grant funding disruptions caused by the Trump administration, according to an analysis in JAMA Internal Medicine.
Anthony G. Letai’s initiation as the 18th director of the National Cancer Institute wasn’t exactly smooth.
